Patient visits wrap up in Parkinson’s trial of oral bezisterim therapy
WHY IT MATTERS
If bezisterim proves effective in this Phase 2 trial, it could offer Parkinson's patients a new oral treatment option that works alone without requiring combination with other medications.
A company called Biovie has finished enrolling patients in a study testing a new oral medication called bezisterim for early-stage Parkinson's disease. The medication is being tested as a standalone treatment that patients could take by mouth. The researchers will now analyze all the data collected, with results expected later this year.
Topline results from a Phase 2 trial testing oral bezisterim as a first-line, stand-alone treatment for early Parkinson’s disease are expected later this year following the completion of the study’s final patient visit. The developer of the therapy, Biovie, announced that researchers will now begin analyzing data from the trial. The trial, called SUNRISE-PD (NCT06757010), is evaluating […] The post Patient visits wrap up in Parkinson’s trial of oral bezisterim therapy appeared